Investigating and resolving drug resistance in lymphoma
One of the core challenges to treating lymphoma is the common occurrence of drug resistance...
Read More...
Focus:
-
![CAR-T therapy manufacturing]()
Draper Q&A: upgrading CAR-T therapy manufacturing
Draper is seeking to update the manufacturing processes and technology used for CAR-T cancer therapies...
Read More...
-
![Bayer BlueRock acquire]()
August’s top news stories
Bayer has signed an agreement to acquire US-based biotechnology company BlueRock Therapeutics for $1bn, and...
Read More...
-
![Vertex Semma acquisition]()
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics...
Read More...
-
![Farxiga's efficacy in heart failure]()
Examining AstraZeneca’s Farxiga: more than a diabetes drug
At the 2019 ESC congress in Paris, AstraZeneca presented full results from the Phase III...
Read More...
-
![]()
Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
Within a year of Japan’s Takeda expressing its interest in buying Shire, the deal had...
Read More...
-
![drugs against aging]()
Beyond cosmetics: repurposing drugs against aging
Identifying and developing drugs that seek to slow the aging process is a relatively new...
Read More...
-
![innovative SMA treatments]()
Treating SMA: moving beyond genetic approaches
As a result of dedicated efforts by the pharma industry, there are now two drugs...
Read More...
-
![Medidata the past and future of R&D]()
Medidata CEO Tarek Sherif on the past and future of pharma R&D
This year marks Medidata’s 20th anniversary; it is the also the year it will be...
Read More...
-
![]()
Tackling Ebola: drugs alone cannot end the outbreak
One year into the latest Ebola outbreak in the DRC, the pharma industry has developed...
Read More...
Go Top
